Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells

The third-generation anaplastic lymphoma tyrosine kinase inhibitor (ALK-TKI) lorlatinib has a unique side effect profile that includes hypercholesteremia and hypertriglyceridemia in >80% of lung cancer patients. Here, we tested the hypothesis that lorlatinib might directly promote the accumulatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Verdura, Sara, Encinar, José Antonio, Fernández-Arroyo, Salvador, Joven, Jorge, Cuyàs, Elisabet, Bosch-Barrera, Joaquim, Menendez, Javier A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456400/
https://www.ncbi.nlm.nih.gov/pubmed/36077379
http://dx.doi.org/10.3390/ijms23179986

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456400/
https://www.ncbi.nlm.nih.gov/pubmed/36077379
http://dx.doi.org/10.3390/ijms23179986

Ejemplares similares